Genelux (GNLX) Interest Expenses (2022 - 2026)

Genelux's (GNLX) quarterly Interest Expenses came in at $336000.0 in Q1 2026, up 314.81% year-on-year from $81000.0 in Q1 2025, and down 99.57% quarter-over-quarter from $78.5 million in Q4 2025.

Genelux (GNLX) Interest Expenses (2022 - 2026) Analysis & Trends

Genelux's Interest Expenses history runs 5 years deep, the most recent figure standing at $336000.0 for Q1 2026.

  • On a quarterly basis, Interest Expenses rose 314.81% year-over-year to $336000.0 in Q1 2026; TTM through Mar 2026 was $336000.0, a 269.7% increase from a year earlier, with the FY2025 full-year figure at $78.5 million, up 29.32% from the prior year.
  • Interest Expenses eased to $336000.0 in Q1 2026 per GNLX's latest filing, from $78.5 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $111.8 million in Q2 2023 and bottomed at -$359000.0 in Q4 2023.
  • The 5-year median for Interest Expenses is $336000.0 (2026), against an average of $18.2 million.
  • Across the five-year window, Interest Expenses slumped 1789.47% in 2023 and jumped 89328.41% in 2025, its largest moves.
  • Year by year, Interest Expenses stood at -$19000.0 in 2022, then slumped by 1789.47% to -$359000.0 in 2023, then jumped by 75.49% to -$88000.0 in 2024, then soared by 89328.41% to $78.5 million in 2025, then tumbled by 99.57% to $336000.0 in 2026.
  • Per Business Quant, the three latest GNLX Interest Expenses figures stand at $336000.0 (Q1 2026), $78.5 million (Q4 2025), and $3.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Oculis Holding AG 66,861.65 Bn 66,861.36 Bn - -42,141.15
2 Nanobiotix 1,935.05 Bn 1,934.98 Bn - -
3 Akari Therapeutics 1,023.69 Bn 1,023.69 Bn - 100,000.00
4 BeOne Medicines 468.59 Bn 463.80 Bn 1.35 Bn 32.89 Mn
5 Vertex Pharmaceuticals 123.01 Bn 115.76 Bn 2.59 Bn 420.30 Mn
6 Regeneron Pharmaceuticals 70.29 Bn 61.53 Bn 3.31 Bn 28.30 Mn
7 Belite Bio 63.33 Bn 63.33 Bn - -
8 Argenx Se 55.70 Bn 50.52 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.79 Bn 34.78 Bn 959.66 Mn 69.29 Mn
10 Genelux 129.36 Mn 129.36 Mn - 336,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 336,000.00
Mar 31, 2026 336,000.00
Dec 31, 2025 78.52 Mn
Dec 31, 2025 78.52 Mn
Sep 30, 2025 3.26 Mn
Sep 30, 2025 3.26 Mn
Jun 30, 2025 493,000.00
Jun 30, 2025 493,000.00
Mar 31, 2025 81,000.00
Mar 31, 2025 81,000.00
Dec 31, 2024 -88,000.00
Dec 31, 2024 -88,000.00
Sep 30, 2024 168,000.00
Sep 30, 2024 168,000.00
Mar 31, 2024 1.65 Mn
Mar 31, 2024 1.65 Mn
Dec 31, 2023 -359,000.00
Dec 31, 2023 -359,000.00
Sep 30, 2023 73.44 Mn
Sep 30, 2023 73.44 Mn